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Antiphospholipid syndrome (APS) is a rare autoimmune disease of unknown etiology that
represents a leading cause of acquired thromboembolism and recurrent miscarriage.
It is characterized by the persistent elevated presence of pathogenic antiphospholipid
auto-antibodies directed against cardiolipin, ß2-glycoprotein-I, and/or a positive lupus
anticoagulant test. As with many autoimmune disorders, the pathogenesis of APS is
believed to be the result of a complex interaction between environmental triggers and
genetic predisposition. Although more common in adults, APS occasionally manifests in
the neonatal period and throughout childhood. Adut-onset APS classification criteria are
poorly validated to the pediatric population (in which pregnancy related complications are
seldom seen) and as a result, assessment of the prevalence of the disease in childhood
is difficult. Thromboembolic events seen in children include deep venous thrombosis
in addition to stroke and pulmonary embolism, which can lead to significant long-term
disability. The disease can be classified as either primary (when occurring in isolation)
or secondary, in which the disease is diagnosed in the context of another underlying
disease, most commonly systemic lupus erythematosus. A variety of laboratory and
clinical difference are seen between pediatric and adult-onset APS. The marked female
predominance seen in adult-onset disease is less evident in childhood where the
gender split is more evenly spread. In addition, children with APS are at a higher risk
of recurrent thromboembolism than adults. The treatment of childhood-onset APS is
challenging due to a lack of large-scale prospective studies in the pediatric population.
Therapeutic options are often based upon treatment guidelines that have been based
upon literature from the adult-onset form of the disease. In the majority of cases,
treatment is focused on the prevention of further thrombosis through treatment with
long-term anti-coagulation therapy. The evidence for the use of antiplatelet agents (such
as aspirin) and hydroxychloroquine is inconclusive. It is important to remember that
anti-coagulation can have significant lifestyle implications for the child with APS and it is
essential to consider potential implications relating to school and recreational activities,
with contact sports often discouraged due to the increased risk of bleeding.
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INTRODUCTION
Antiphospholipid syndrome (APS) is a rare autoimmune
disorder characterized by recurrent pregnancy morbidity (PM)
and vascular thrombosis (VT). It occurs in the presence of
persistent pathogenic antiphospholipid antibodies (aPL) (1).
These are a heterogenous group of antibodies directed against
glycoproteins (2). Standard testing of these antibodies in clinical
practice include detecting those directed against cardiolipin
(aCL) and/or ß2-glycoprotein-1 (ß2GPI) by enzyme-linked
immunosorbent assay (ELISA). In addition, a functional
coagulation assay is used to test for the presence of the
circulating lupus anticoagulant (LAC) (3). These antibodies
must be persistent, with classification criteria emphasizing the
importance of positive tests being repeated at an interval of no
>12 weeks (4). It is essential that a positive test is repeated as
a number of alternate conditions may result in a false positive
detection of aPL antibodies. This includes a variety of infections,
most classically syphilis (5). The diagnosis of APS may be
complicated further by the fact that no one single assay is able
to identify all pathogenic antibodies related to the disease (6).
The most common presentations of the disease are often
the result of PM and VT in adults. With regards to pregnancy
related symptoms, these more frequently present with recurrent
fetal loss. Less commonly the disease may be associated with
pre-eclampsia and pre-term delivery (7, 8). Vascular thrombotic
manifestations include both venous and arterial systems such as
deep vein thrombosis (DVT), pulmonary embolism (PE), stroke,
transient ischemic attack (TIA), and myocardial infarction
(MI) amongst the most frequently seen events in adults
(9, 10). Classical cutaneous manifestations including livedo
reticularis has long been associated with APS. Patients may
develop neurological symptoms including chorea and epilepsy.
Other than VT, other hematological manifestations such as
thrombocytopenia and hemolytic anemia are also commonly
seen in association with the disease (11, 12).
Although there are a number of features that are in common
with adult onset disease, there are numerous key differences
that are unique in the case of children who develop APS. PM
is often not applicable to the pediatric population and the
risk of VT is similarly lower than in adult populations, thus
making the diagnosis of APS in children challenging (13, 14).
Furthermore, decisions relating to anti-coagulant treatment in
young patients with the disease requires careful consideration
and have potentially significant effects on lifestyle of the child and
their family. In the context of pediatric-onset APS, there is a lack
of evidence relating to both treatment and long-term outcomes
with consensus drawn from a number of small studies and case
reports. Recommendations for treatment are often derived from
the study of the disease in larger adult populations (14).
PATHOGENESIS OF APS
Although the exact pathogenesis of APS is not fully understood,
significant advances have been made in recent years with regards
to gaining a greater understanding of the underlyingmechanisms
that drive the development of the disease. It is believed that a
combination of abnormalities in endothelial cells, monocytes and
complement play a key role the development of both PM and VT.
In terms of the pathogenesis of APS, the “two hit” hypothesis
is the most well described and widely accepted mechanism of
thrombus formation. This pathogenic principle is supported by
the fact that the clinical symptoms of VT and PM only occur
occasionally despite the persistent presence of aPL antibodies.
This importantly highlights that antibodies alone do not explain
the whole clinical picture. The so called “first hit” occurs as a
direct consequence of aPL antibodies, which results in activation
of platelets, monocytes, and endothelial cells. Furthermore,
aPL antibodies induce downregulation of naturally occurring
anticoagulants and impair fibrinolysis (15–18). This lowers
the threshold for developing a thrombotic event. The “second
hit” relates to an additional factor that further exacerbates
a pro-thrombotic state (for example inflammation), which in
combination with aPL antibodies ultimately induces thrombosis
(19). The theory of a “second hit” is further supported by recent
studies, which have implicated Toll Like Receptors (TLR) in
mediating the inflammatory response in the pathogenesis of APS
(20, 21). However, in the context of pediatric APS, there is a
notable absence of other classical pro-thrombotic risk factors
including both pathological states (such as hypertension) and
lifestyle related factors such as smoking. Therefore, this may
suggest that another key risk factor is present in the children
who develop the disease. Registry data suggests that the rates of
APS associated with malignancy (another pro-thrombotic state)
are significantly lower in patients with pediatric APS (<1% of
cases) when compared with adults with the disease, which can
be associated with solid organ malignancies (22, 23). This may
similarly suggest that the so-called “second hit” in childhood is
the result of an alternative mechanism or is acting via a different
pro-thrombotic state than is seen in adults with the disease.
It is obvious that thrombus formation is central to the
VT manifestations of APS but it should also be noted that
this has been implicated in the PM related complications of
the disease. The main mechanism associated with fetal loss
is suggested to be due to the result of thrombus formation
within the placental vasculature, which causes an impairment in
maternal-fetal blood exchange (24). In addition, in many cases
of PM related complications of APS, histological examination of
the placenta has demonstrated the presence of thrombosis and
infarction (25–27).
As with many autoimmune diseases, APS is believed to occur
as a result of a complex interaction of environmental and genetic
factors. It has been suggested that a loss immune tolerance
is induced by bacterial or viral antigens that contain similar
sequences to phospholipids and results in cross reactive T cells
(28, 29). In terms of the underlying genetic basis of APS, a
number of associations have been identified from studies in
both familial and non-familial cases of the disease. In particular,
human leukocyte antigen (HLA)-DR, and DQ haplotypes show
the most consistent association with the disease (30, 31). A
variety of loci have been implicated with a susceptibility for APS
including HLA-DR4, DR7, DR9, DR13, DR53, DQ6, DQ7, and
DQ8 major histocompatibility complex II (MHC II) alleles (32).
Animal studies further support a genetic basis to the disease
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with MHC II identified as being vital for producing aPL after
immunization with ß2GPI (33). Several non-MHC genes have
been shown to increase the susceptibility for APS including IFR5
and STAT4 (34, 35).
DIAGNOSIS
The diagnosis of APS in childhood is often a challenge for
clinicians as young patients display a number of key difference
when compared with those who present with the disease in
adulthood. Given the lack of large prospective studies of the
disease in children it is difficult to estimate the prevalence of the
disease in this group with any certainty. In 2004, the pediatric
APS (Ped-APS) registry was established as a collaborative project
between the European Forum of Antiphospholipid syndrome
and the Juvenile Systemic Lupus Erythematosus Working Group
of the Pediatric Rheumatology European Society (PReS). The
aim was to undertake global multicentered controlled studies
in a large group of young patients with APS. Results from the
international registry reviewing characteristics from 121 patients
with pediatric APS found the mean age of onset was 10.7 years,
with APS reported in neonates and throughout the adolescent
period (22). Cases of pediatric APS showed an even split between
males and females (1:1.2) (36). In adult-onset disease, there is a
female predominance quoted in the region of 1:5 (37). This is
similar to the data on systemic lupus erythematosus (SLE), in
which adult-onset disease shows a propensity to effect females
(1:9 males to females), whereas in pediatric and juvenile-onset
disease SLE the ratio is closer 1:5 and in the pre-adolescent
population closer to 1:1 (38).
Definitions and Classification Criteria
Pediatric APS is defined as the onset of APS in those under
the age of 18 years old (39). In both pediatric and adult-
onset APS, the disease can be defined as either primary or
secondary APS. Secondary APS refers to the state in which
the disease occurs in combination with another connective
tissue disease (CTD). Secondary APS in children is most
commonly associated with systemic lupus erythematosus (SLE)
(37). The disease has also been described in children with various
coexisting disorders including juvenile idiopathic arthritis
(JIA), juvenile dermatomyositis, Henoch-Schönlein purpura,
autoimmune thyroiditis, hemolytic-uremic syndrome, Behçet’s
disease, rheumatic fever and malignancy (22, 40–44).
In the absence of another disease the condition is defined
as primary APS. Although poorly defined between 38 and 50%
of cases of childhood-onset APS are said to be primary (22).
In comparison, primary APS in adults is said to account for
more than half of cases (45). The lower proportion of primary
APS seen in children may due to the low incidence of PM
seen in children, but may also be related to an ascertainment
bias if children without a known autoimmune disease are less
frequently investigated for aPL when presenting with a VT event.
Furthermore, a number of cases of primary pediatric APS are
later revised as secondary APS after a subsequent diagnosis of SLE
is made (36, 46). The proportion of patients who progress from
primary to secondary forms of the disease are said to be higher in
those who develop the disease during childhood when compared
with those who suffer from the adult form of the disease (46, 47).
The study of pediatric-onset APS is complicated by the
fact that the diagnostic criteria used in adults is not reliably
validated in children as a key feature relates to the occurrence
of PM. The updated Sapporo criteria for adult-onset APS
is defined in Table 1 (4). Currently there is no universally
accepted validated diagnostic criteria for pediatric APS. This
poses a variety of challenges in particular with regards to
conducting research and clinical trials. In 2016, the Single
Hub and Access point for pediatric Rheumatology in Europe
(SHARE) initiative highlighted that whilst the adult criteria
for APS were specific for pediatric-onset disease they lacked
sensitivity. Recommendations from the group presented at the
15th International Congress on Antiphospholipid Antibodies
suggested that new classification criteria are required for pediatric
APS and these should incorporate both thrombotic and non-
thrombotic manifestations of the disease (48).
Clinical Features
A number of small studies have found that the most common
presenting feature of pediatric APS is venous thrombosis in
particular those involving the lower limbs (predominantly in
the form of deep vein thrombosis) (22, 49). Arterial and
small vessel thrombosis are the next most commonly observed
manifestation (22). The cerebral circulation is the most common
site of arterial thrombosis, but it also occurs within the retinal,
coronary, hepatic andmesenteric circulation (50). Complications
of thrombosis, often in combination with Raynaud’s, can also
include digital ulceration. These are rarely seen in children and
so should raise suspicion of APS in any young patient presenting
with these symptoms. Recent data, including results from the
Ped-APS registry, has indicated that patients with pediatric APS
are at an increased risk of recurrent thrombosis when compared
with the adult-onset form of the disease (22, 51). Whether this is
related to a more severe pathogenic phenotype or issues related
to treatment such as adherence remain poorly understood.
Cerebral ischemia may occur as a result of cranial arterial
thrombosis resulting in stroke or TIA. Both of these are
extremely rare in childhood and therefore a diagnosis of APS
should be considered in all cases (52, 53). Interestingly, Ped-
APS registry data suggests that the incidence of cerebrovascular
events as a proportion of overall APS are said to be higher
in pediatric APS than in adults with the disease (22). Non-
thrombotic neurological symptoms can also be non-specific
and include migraine and headache (54). A wide variety of
additional features of central nervous system (CNS) related
APS symptoms include epilepsy, chorea and transverse myelitis
although unlike adults with APS, these have been reported
as isolated case reports and are less common manifestations
when compared to adult onset APS (14, 55, 56). In addition,
thrombosis can cause a variety of ocular disorders including
amaurosis fugax and ischemic retinopathy secondary central
retinal artery/venous occlusion (57–59). Myocardial infarction
(MI) may be the result of coronary thrombosis secondary to
APS and carries a high risk of mortality (60, 61). In addition,
valvular heart disease is another rare manifestation of the disease
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TABLE 1 | The 2006 update Sapporo Criteria for a diagnosis of antiphospholipid syndrome (APS) requires at least 1 of the following clinical criteria and 1 of the following
laboratory criteria.
Clinical criteria Vascular thrombosis (VT)
One or more clinical episodes of arterial, venous, or small vessel thrombosis in any tissue or organ. Thrombosis must be confirmed by
objective va lidated criteria. For histological confirmation, thrombosis should be present without significant evidence of inflammation
in the vessel wall. This can be further subclassified as being in the presence or the absence of additional risk factors for thrombosis.
Pregnancy morbidity (PM)
One or more unexpla ined deaths of morphologically normal fetuses at or beyond the l0th week of gestation, with normal feta l
morphology documented by ultrasound or by direct examination of the fetus;
1 or more premature births of morphologically normal neonates before the 34th week of gestation because of eclampsia or severe
pre-eclampsia defined according to standard definitions or recognized features of placental insufficiency;
3 or more unexpla ined consecutive spontaneous abortions before the lOth week of gestation, with maternal anatomical or hormonal
abnormalities and paternal and maternal chromosomal causes excluded.
Laboratory
criteria
Lupus anticoagulant is present in the plasma
Anticardiolipin antibody of IgG or IgM isotype in serum or plasma is present in medium or high titer (>40 IgG phospholip id [GPL]
units or IgM phospholipid [MPL] units, or >99th percentile), by ELISA
Anti-beta2-glycoprotein I antibody of IgG and I or IgM isotype in serum or plasma (in titer >90th percentile). by ELISA
Laboratory criteria must be positive on 2 or more occasions,at least 12 weeks apart.
(62). In terms of pulmonary manifestations of pediatric APS,
pulmonary thromboembolism is a frequent presenting symptom
of the disease and should raise the clinical suspicion of the
diagnosis of APS in any child in the absence of an alternate cause
for thrombosis (63, 64). Pulmonary hypertension may result
from chronic pulmonary vaso-occlusive disease and typically is
associated with poor long term outcomes (49). Furthermore,
pulmonary fibrosis has also been described in the context of
pediatric APS (although the majority of cases are in those with
coexisting SLE) (57). Thrombosis related renal manifestations
of pediatric APS including thrombotic microangiopathy and in
some cases this may result in end stage renal failure necessitating
renal replacement therapy (65, 66). Cases of focal proliferative
glomerulonephritis has also been described in pediatric primary
APS (66, 67). Furthermore, bilateral adrenal infarction secondary
to thrombosis has also been reported as a rare cause of primary
adrenal insufficiency in children with primary APS (68).
In addition to thrombosis, it is now universally accepted
that a wide array of systemic symptoms that are also frequently
seen in adult-onset disease are similarly associated with the
pediatric form of the disease. These more generalized symptoms
include dermatological manifestations, which can range from
classical livedo reticularis to the more rarely seen severe
complication of purpura fulminans (69). Aside from thrombosis,
various hematological disorders have been reported in the
context of pediatric APS including hemolytic anemia, leukopenia,
thrombocytopenia and cryoglobulinemia (70).
The various clinical manifestations of pediatric APS are
summarized in Table 2.
Serological Abnormalities in APS
As outlined in Table 1, the diagnosis of APS occurs in the
context of persistently positive aPL antibodies. Pediatric-onset
APS demonstrates a variety of key serological differences
when compared with adult-onset disease. The most commonly
occurring aPL antibody in pediatric APS is directed against
cardiolipin, which has been quoted as being present in
approximately 80% of cases. In comparison, this has been
TABLE 2 | Clinical features associated with pediatric antiphospholipid syndrome.
Neurological Transverse myelitis
Migraine
Chorea
Cognitive impairment
Seizures
Stroke I trans ient ischemic attack
Venous sinus thrombosis
Ocular ischemia
Hematological Venous thrombosis
Arterial thrombosis
Thrombocytopenia
Leukopenia
Hemolytic anemia
Dermatological Livedo reticularis
Raynaud ’s phenomenon
Purpura fu lminans
Cardiovascular Myocardial infarction
Cardiac valvular disease
Pulmonary Pulmonary embolism
Pulmonary hypertension
Interstitial fibrosis
Renal Antiphospholipid nephropathy
Renal thrombotic microangiopathy
Endocrine Primary adrenal insufficiency (secondary
to adrenal infarction)
reported to be positive in only just over half of adult cases
of APS. In addition, LAC is seen in approximately 70-90%
of pediatric patients with APS and by comparison is present
in half of adult cases (22, 71). The presence of a persistently
positive anti-ß2GPI antibody was found to be similar in both
adult and pediatric forms of the disease. Multiple positivity
is also a common finding in pediatric APS (71). A study by
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Avcˇin et al., in which auto-antibody titers were measured in
61 cases of pediatric APS suggested that the normal ranges
for these antibodies are different from those used in adult
cases. Furthermore, a high proportion of transient aPL antibody
positivity was seen in children without the symptoms of APS
and this was felt to be likely related to previous exposure to
infection (72).
In recent years the role of antibodies to the amino-terminal
domain of ß2GPI, domain 1 (DI), have been studied in detail
in adults with APS. This has been shown to represent the
pathogenic sub-population of anti- ß2GPI antibodies, directed
against a conformational epitope present in the first domain of
ß2GPI. Studies have identified that anti-DI antibodies are present
in patients with APS and are associated VT manifestations of
the disease (73). There is also evidence to suggest that anti-DI
antibodies may be present in the absence of other aPL antibodies
in cases of so called “seronegative APS” (74). Currently there are
however no studies of the prevalence of anti-DI antibodies in
childhood onset APS.
In the context of pediatric secondary APS, it is important
to screen for other auto-antibodies that may be indicative an
additional autoimmune process such as SLE. In particular,
hypocomplementemia and antibodies directed against nuclear
components; including anti-nuclear antibodies (ANA);
extractable nuclear antigens (ENA) inclusive of anti-Ro,
anti-La, anti-Sm and anti-RNP; and anti-double stranded DNA
(dsDNA) antibodies should prompt the clinician to consider a
diagnosis of a connective tissue disease or lupus. In addition,
it is important to screen any child with suspected SLE for the
presence of aPL (75). A number of small studies have examined
for the presence of aPL antibodies in juvenile-onset SLE (JSLE).
ACL positivity has been reported to be present in 19–89% of
patients with JSLE, whilst LAC has been described in between 10
and 62% of cases (76–79).
The key differences between pediatric onset APS and the adult
onset form of the disease are summarized in Table 3.
TREATMENT AND LONG-TERM
OUTCOMES
Prompt recognition of the disease and early initiation of
treatment is vital so as to reduce the long-term sequelae of
VT related symptoms in childhood APS. Residual neurological
deficit from cerebral thrombosis may result in a number of
development delays in both motor and cognitive function. It is
however important to consider that in the majority of cases of
pediatric APS the first presentation of the disease is with VT
and so there is often little that can be done in terms of primary
prevention. In view of the scarcity of cases of pediatric APS,
there is little in the way of prospective studies in particular
with regards to stratifying treatment of the disorder. Treatment
recommendations are therefore usually adapted from evidence
based in the literature of adult-onset disease.
The management of pediatric APS however poses a number
of importance considerations that are unique to this age group.
In view of this the SHARE initiative was launched in order to
TABLE 3 | Key clinical and seroloe:ical differences between pediatric and
adult-onset APS.
Pediatric onset APS Adult onset APS
PM related symptoms are rarely seen in
the pediatric population in view of the fact
that the incidence of pregnancy in this age
group is low and limited to the
adolescent population
Disease commonly manifests with
PM and I or VT related symptoms
No pediatric specific diagnostic criteria
available
The updated Sapporo Criteria are
a reliable and reproducible
diagnostic criteria of high sensitivity
and specificity
Often occurs in the context of no other
classical pro- thrombotic risk factors
Disease may present in the setting
of additional pro- coagulant risk
factors including atherosclerosis
and hypertension
Typical even incidence between males and
females (l: 1.2)
Female predominance (1:5)
Primary APS accounting for between
38-50% of cases
Primary APS accounting for more
than half of cases
Most common presenting symptom is VT;
predominantly in the lower limb. PM
symptoms seldom seen due to the low
incidence of pregnancy in
the pediatric group
Patients may present with either
VT or PM related symptoms
Antibodies directed against aCL are most
commonly
occurring APS antibody (80%)
Antibodies directed against aCL
are seen in just over half of adult
cases
develop an evidence base for rare rheumatic diseases in childhood
including APS.
Anti-coagulation
The recommendations for treatment were published in 2017
and suggested the use of long-term anticoagulation (most
commonly with warfarin) in the case of any child with
a positive aPL antibody and venous thrombosis (80). For
arterial VT it was also recommended that in addition to
long-term anticoagulant therapy consideration for combination
therapy with anti-aggregation / anti-platelet agents such
as aspirin or clopidogrel should also be considered. In
the occurrence of recurrent thrombosis oral anticoagulation
should be continued although the target INR should be
increased from 2.0–3.0 to 3.0–4.0. Consideration should
also be made for alternate therapies in this incidence, for
example extended courses of low molecular weight heparin
(LMWH) (80).
Anti-platelet Agents in Primary Prophylaxis
When considering initiating treatment, it is important to
consider any additional pro-thrombotic risk (81). In the context
of primary thromboprophylaxis against VT (for example in
asymptomatic patients with persistently positive aPL antibodies),
the use of low-dose aspirin has been recommended. However,
in the adult literature, one small placebo-controlled trial of the
use of aspirin failed to show any benefit from the treatment
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after 2 years of follow-up and so the role of aspirin remains
debatable (82).
The Role of Immunosuppression
In the primary prophylaxis of pediatric secondary APS
coexisting with SLE, the SHARE initiative recommended
the use of hydroxychloroquine in addition to aspirin (80).
Hydroxychloroquine is also thought to offer anti-thrombotic
properties(83).
The role for immunosuppressive treatment in the
management of primary childhood APS is uncertain.
Recent observational studies have found that a number of
patients are treated with corticosteroids in addition to other
immunosuppressants, however there is no clear evidence to
support the routine use in clinical practice. In the context
of secondary pediatric APS, a larger group of patients are
on concurrent steroid and immunosuppressive treatment
although this is typically targeted to the management of CTD
symptoms (64).
In the adult literature, rituximab (a chimeric anti-CD20
monoclonal antibody) has been shown to result in significant
reduction in IgG aCL antibodies in patients receiving treatment
for SLE. However, there are currently no detailed studies of the
role of B-cell depletion therapy in either adult or pediatric cases
of APS (84).
Newer Oral Anti-coagulants
Newer therapeutic targets are now being investigated in adult-
onset APS. The RAPS trial recently investigated the use of
rivaroxaban (an oral direct factor Xa inhibitor) in comparison
to warfarin (the current standard of care in APS) as a treatment
of APS in patients with previous venous thromboembolism.
The study concluded that there was no increase in thrombosis
in patients treated with rivaroxaban in comparison to those
taking warfarin (85). The advantage of rivaroxaban is the wider
therapeutic window and not monitoring of any markers of
coagulation is necessary. However, there are only case reports
of the use of rivaroxaban in children with APS and its routine
treatment at the point in time of writing this chapter in children
with APS is not recommended (86).
Key considerations in the diagnosis and management of
pediatric onset APS are summarized in Table 4.
Treatment Considerations in Pediatric APS
The treatment of APS in childhood is complicated further by a
number of key factors that are highly relevant to the management
of any young patient with a chronic illness that need to be
considered by the treating physician. It is well documented
that adherence with treatment in rheumatic diseases amongst
adolescent patients is lower than adults. In particular, studies
have found that problems with adherence are more likely to
be seen in children taking three or more different types of
medicine a day (87). In addition to poor adherence with oral
anticoagulants, problems occur with LMWH that is given by
subcutaneous injection, especially as these injection are often
reported to be painful. As this therapy has a shorter half-life than
warfarin the implications of missing even occasional doses are
TABLE 4 | Key considerations relating to the diagnosis and management of
pediatric APS.
• Lack of PM related symptoms seen in pediatric-onset APS thus rendering
widely accepted c lassification for APS unreliable in the childhood cases
• All children with unproved thromboembolic disease should be screen for
aPL antibodies
• Young patients with JSLE should be routine ly screened for aPL antibodies
• It is important to consider a variety of widespread systemic symptoms
associated with APS
• Management centers on anticoagulation to reduce the risk of VT
• Oral anticoagulants (such as warfarin) are the first line treatment although
newer agents such as rivaroxaban are currently be assessed for use in
adults
• CAPS accounts for <1% of cases of pediatric APS but can be the
presenting symptom of the disease
• Prompt diagnosis and initiation of treatment with both anticoagulation and
immunosuppression is essential in CAPS
• Essential to ensure both young patients and their families are educated in
the treatment of the disease
• It is vital to check regularly adherence with medication, in particular
throughout the adolescent period
especially significant and increase the risk of further VT. The
rates of recurrent thrombosis are higher in pediatric cases of APS
than in adults although it is not clear as to whether this is in
relation to more aggressive disease or as a result of adherence
with treatment.
Furthermore, it is essential that the treating clinician considers
the wide-ranging implications of anticoagulant therapy which
may raise issues regarding education and leisure activities.
Patients are discouraged from participating in contact sports and
therefore may not be able to fully participate in a variety of leisure
activities both in and out of school. Another area that requires
lifestyle modification for the young patient with APS relates to
the use of alcohol, which can interact with warfarin therapy.
It is therefore essential that patient education is maintained
throughout the adolescent period.
SPECIAL CIRCUMSTANCES
Catastrophic APS in Children
Catastrophic APS (CAPS) represents the most acute and
severe manifestation of APS. This is characterized by the
rapid development of widespread thrombosis in the micro-
circulation of several organs resulting in multi-organ failure. It
is associated with high rates of mortality and morbidity, even
with rapid diagnosis and optimal treatment. The occurrence
of CAPS in the population of children with APS is difficult
to quantify and in adult onset disease is believed to account
for approximately 1% of all cases with APS (88). Data from
the CAPS Registry of more than 400 patients with CAPS
has suggested that approximately 10% of cases were seen in
those under the age of 18 years (89). When compared with
adult onset disease, pediatric CAPS was far more likely to
be the presenting symptom of the disease (87% of pediatric
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cases presented with CAPS in comparison to 45% of adult
cases). The risk of mortality from CAPS in pediatric cases was
26%, which is lower than the mortality rate reported in adults
(which can be as high as 50%) (89, 90). Registry data also
found that pediatric-onset disease is more frequently seen in
relation to preceding infection when compared with the adult
population (89).
The treatment of APS in pediatric cases is based upon
therapies that have been suggested to be of benefit in adult-onset
disease. There are no large-scale studies that have assessed
treatment of CAPS in either adult or pediatric populations
however. Management revolves around a combination of
anticoagulation and immunosuppression (90). There is
little in the way of consensus regarding the most effective
immunosuppressive treatment regime although patients are
often treated with a combination of drugs. CAPS registry
data found that the vast majority of pediatric cases are treated
with corticosteroids (76% of patients). In addition to steroids,
pediatric patients are often treated with concomitant plasma
exchange, cyclophosphamide and intravenous immunoglobulin
(IVIg) therapy (89). The use of cyclophosphamide in pediatric
cases must be carefully considered in view of the possible
implications for future fertility. Gonadotrophic protection
should be considered on a case-by-case basis. In the literature,
there is evidence to support the use of B-cell depletion therapy
with rituximab in cases of both adults and children with CAPS
(91, 92).
Neonatal APS
The onset of APS in neonatal period is an unusual manifestation
of the disease. The infant coagulation system shows a number
of key differences when compared with adults and this may
contribute to onset of the disease in the neonatal period. In the
context of pediatric APS it is important to consider the role of
naturally occurring anticoagulants such as Protein C and Protein
S, which are seen at a lower levels in the neonatal circulation
(93, 94). In addition, neonatal plasminogen levels are typically
lower than in adults and platelet aggregation is decreased
throughout the first year of life (94). Clinical features including
any VT, in particular stroke, should prompt consideration of a
diagnosis of neonatal APS. It is often difficult to differentiate
between neonatal APS and other hereditary pro-thrombotic
disorders and therefore early specialist input is essential in such
cases.
Children Born to Mothers With APS
Recent studies have focused on the outcomes for children born
to mothers with APS. Registry data has observed that aCL
antibodies can be detected in newborns suggesting that the
antibody is able to cross the placenta. These antibodies typically
clear the infant’s circulation within the first six months of life.
In addition, the occurrence of VT these infants are rare (95).
Interestingly, it has also been reported that ß2GPI are seldom
able to cross the placenta and contribute little in the way of
prothrombotic risk to the newborn (96). In a study of 134 babies
born to mothers with APS there were no cases of neonatal
thrombosis of SLE (97).
CONCLUSIONS
In conclusion, cases of APS have been described in children
of all ages with the disease occasionally manifesting in the
neonatal period. The disease is rare in childhood but should
be considered in all cases of unprovoked thromboembolic
disease. Furthermore, all patients with JSLE should be
screened for secondary APS. A number of key differences
are seen when comparing the disease in childhood with
the more well described adult onset form of the disease.
Evidently the rates of PM related symptoms are seldom
seen in the childhood form of the disease. Children with
APS are also at an increased risk of recurrent thrombotic
events when compared with adults and so it is essential to
maintain long-term anticoagulant therapy. There is a lack
of prospective studies in the field of pediatric APS and so
treatment recommendations are largely adapted from adult
studies. Pediatric APS represents a leading cause of VT in
childhood and can result in potentially devastating long-term
complications.
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